Mouse Models as a Tool for Understanding Progression in Braf(V600E)-Driven Thyroid Cancers
- Author:
Iñigo LANDA
1
;
Jeffrey A KNAUF
Author Information
- Publication Type:Review
- Keywords: Proto-oncogene proteins B-raf; Thyroid neoplasms; Mice, transgenic
- MeSH: Animals; Carcinogenesis; Catalytic Domain; Mice; Mice, Transgenic; Negotiating; Proto-Oncogene Proteins B-raf; Proto-Oncogenes; Telomerase; Thyroid Gland; Thyroid Neoplasms
- From:Endocrinology and Metabolism 2019;34(1):11-22
- CountryRepublic of Korea
- Language:English
- Abstract: The development of next generation sequencing (NGS) has led to marked advancement of our understanding of genetic events mediating the initiation and progression of thyroid cancers. The NGS studies have confirmed the previously reported high frequency of mutually-exclusive oncogenic alterations affecting BRAF and RAS proto-oncogenes in all stages of thyroid cancer. Initially identified by traditional sequencing approaches, the NGS studies also confirmed the acquisition of alterations that inactivate tumor protein p53 (TP53) and activate phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced thyroid cancers. Novel alterations, such as those in telomerase reverse transcriptase (TERT) promoter and mating-type switching/sucrose non-fermenting (SWI/SNF) complex, are also likely to promote progression of the BRAF(V600E)-driven thyroid cancers. A number of genetically engineered mouse models (GEMM) of BRAF(V600E)-driven thyroid cancer have been developed to investigate thyroid tumorigenesis mediated by oncogenic BRAF and to explore the role of genetic alterations identified in the genomic analyses of advanced thyroid cancer to promote tumor progression. This review will discuss the various GEMMs that have been developed to investigate oncogenic BRAF(V600E)-driven thyroid cancers.
